We all know smoking is bad for you but scientists have now discovered people who have sleep apnoea - known as the silent killer - are putting themselves in even greater danger of future health complications.
In a first study of its kind, scientists from the Heart Research Institute (HRI) have made the link between amounts of nicotine in the blood and the amount of time people have less oxygen while they’re sleeping.
Sleep apnoea occurs when a person’s throat and upper airway become partly or completely blocked during sleep, causing short periods where breathing stops.
In a new paper published in ESC Heart Failure, HRI scientists found increases in nicotine levels were associated with a 2.3 minute increase in the time spent with oxygen saturations below 90 per cent.
One of the markers of severity of sleep apnoea is time spent with an oxygen saturation less than 90 per cent.
“We know smoking is bad for the heart – it’s one of the major risks for heart attacks – and although smoking is known to reduce oxygen concentration in the blood, the interaction of smoking with sleep apnoea has not been quantified. Using blood concentrations of the major nicotine metabolite, we were able for the first time to quantify the effect of smoking on oxygen concentrations at night in people with sleep apnoea.
“A standardised increase in levels of this metabolite was associated with 2.3 more minutes with an oxygen concentration less than 90 per cent in people with sleep apnoea. Time with an oxygen concentration less than 90 per cent is a proven indicator of bad cardiovascular outcome.”
Scientists know sleep apnoea and congestive heart failure commonly co-exist but with their interaction unclear, Dr O’Sullivan’s team used hundreds of small molecules called metabolites to understand this interaction.
“Believe it or not, stiff heart failure – when the heart muscle can still pump blood but is stiff and cannot relax properly – is the most common form of heart failure today and we have almost no treatment options,” Dr O’Sullivan said.
Metabolomics is a relatively new field of study that investigates metabolites, which are the components of your metabolism and play key roles in disease. They can provide insight into how one disease is linked to another, like in this case the consequences of sleep apnoea and heart failure. Several metabolites are also key fuels for the working heart, and others form the units of energy by which the heart works.
The team studied metabolites and lipids in 1,919 people from the Framingham Heart Study and 1,524 participants of the Women’s Health Initiative, both US studies.
Dr O’Sullivan said Framingham was known as the “town that changed America” because of the multi-generational study that started in 1948 that subsequently identified the cardiovascular risk factors we still use today. Much research using this study is openly available internationally, enabling researchers around the world.
“Accurate measurement of disease combined with blood metabolite levels is far more accurate than self-reported questionnaires – that’s one of the strengths of this study,” he said.
Although sleep apnoea is very common (up to one in four adults), its consequences and interactions with other diseases remain poorly understood. There are almost no studies with sleep study data, heart failure data, and metabolomic data in the same individuals – this is a major novelty of this study.
Other findings in this study include new insights into the relationship between lipid storage, energy storage, and heart size and structure.
Dr Melissa Farnham, who was involved in the study, is the leader of the Cardiovascular Neuroscience Group at HRI, and her research focuses on how the brain responds to sleep apnoea.
Other media coverage
Image: Dr John O'Sullivan, Cardiometabolic Disease Group Leader and Clinical-Academic Cardiologist